EyePoint, Inc. Announces Topline LUGANO Phase 3 Results for DURAVYU

What Happened

• On August 17, 2026, EyePoint, Inc. announced topline data from LUGANO, a pivotal Phase 3 clinical trial evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD). The company issued a press release (filed as Exhibit 99.1) and posted an updated investor presentation on its website (filed as Exhibit 99.2).

Key Details

• Date of announcement: August 17, 2026.
• Trial: LUGANO — a pivotal Phase 3 study of DURAVYU for wet AMD.
• Materials filed with the 8‑K: press release (Exhibit 99.1) and investor presentation (Exhibit 99.2).
• Company website where the presentation was posted: www.eyepoint.bio.

Why It Matters

• Topline Phase 3 results are a major clinical milestone that can affect the company’s regulatory path, potential approval timeline, and commercial prospects for DURAVYU.
• The 8‑K itself attaches the announcement and presentation but does not include detailed trial data in the filing; investors should review the linked press release and investor presentation for specific efficacy, safety, and next‑step information.